Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) EBITDA (2016 - 2026)

Corvus Pharmaceuticals' EBITDA history spans 12 years, with the latest figure at -$13.9 million for Q1 2026.

  • Quarterly EBITDA fell 191.43% to -$13.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$44.0 million through Mar 2026, down 6.43% year-over-year, with the annual reading at -$14.9 million for FY2025, 76.22% up from the prior year.
  • EBITDA came in at -$13.9 million for Q1 2026, down from -$12.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $15.2 million in Q1 2025 to a low of -$39.6 million in Q3 2024.
  • The 5-year median for EBITDA is -$8.2 million (2022), against an average of -$9.6 million.
  • Year-over-year, EBITDA plummeted 551.85% in 2024 and then soared 353.4% in 2025.
  • Corvus Pharmaceuticals' EBITDA stood at -$9.2 million in 2022, then surged by 32.76% to -$6.2 million in 2023, then tumbled by 105.0% to -$12.7 million in 2024, then increased by 4.0% to -$12.2 million in 2025, then dropped by 14.52% to -$13.9 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's EBITDA are -$13.9 million (Q1 2026), -$12.2 million (Q4 2025), and -$10.1 million (Q3 2025).